"[citation needed] Octapharma was founded in 1983 by Wolfgang Marguerre, a German businessman who had previously worked in the pharmaceutical industry.

The name Octapharma is derived from the Greek word for eight, referring to Factor VIII, the blood clotting protein deficient in patients with haemophilia A. Octapharma's inaugural product was the first Factor VIII concentrate using what was then innovative solvent detergent virus inactivation technology.

[8] Patients in 118 countries are treated with products in the following therapeutic areas: Octapharma medicines treat a broad range of rare and life-threatening congenital and acquired diseases and conditions: Octapharma converts source plasma into plasma protein products through fractionation and processing.

As of December 31, 2022, Octapharma employs around 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Hematology, Immunotherapy and Critical Care.

Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centers across Europe and the US.